Population pharmacokinetics/pharmacodynamics modeling: Parametric and nonparametric methods

被引：37
|
作者：
Jelliffe, R [1 ]
Schumitzky, A [1 ]
Van Guilder, M [1 ]
机构：
[1] Univ So Calif, Sch Med, Div Geriatr Med, Lab Appl Pharmacokinet, Los Angeles, CA 90033 USA
来源：
THERAPEUTIC DRUG MONITORING | 2000年 / 22卷 / 03期
关键词：
population pharmacokinetic modeling; pharmacodynamic modeling; parametric methods; nonparametric methods;
D O I：
10.1097/00007691-200006000-00019
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
As clinicians acquire experience with the clinical and pharmacokinetic behavior of a drug, it is usually optimal to record this experience in the form of a population pharmacokinetic model, and then to relate the behavior of the model to the clinical effects of the drug or to a linked pharmacodynamic model. The role of population modeling is thus to describe and record clinical experience with the behavior of a drug in a certain group or population of patients or subjects.
引用
收藏
页码：354 / 365
页数：12
相关论文
共 50 条
  • [21] SIMULTANEOUS MODELING OF PHARMACOKINETICS AND PHARMACODYNAMICS
    STANSKI, DR
    VOZEH, S
    SHEINER, LB
    CLINICAL RESEARCH, 1979, 27 (01): : A74 - A74
  • [22] MODELING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TRIMAZOSIN
    KELMAN, AW
    MEREDITH, PA
    ELLIOTT, HL
    REID, JL
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1986, 7 (04) : 373 - 388
  • [23] Population Modeling and Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Isoniazid in Lungs
    Lalande, L.
    Bourguignon, L.
    Bihari, S.
    Maire, P.
    Neely, M.
    Jelliffe, R.
    Goutelle, S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (09) : 5181 - 5189
  • [24] Parametric and nonparametric population modeling: An impression and a fact about parameter precision
    Bustad, A
    Terziivanov, D
    Leary, R
    Port, R
    Jelliffe, R
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 248 - 248
  • [25] Comparison of parametric and nonparametric methods for modeling height-diameter relationships
    Adamec, Zdenek
    Drapela, Karel
    IFOREST-BIOGEOSCIENCES AND FORESTRY, 2017, 10 : 1 - 8
  • [26] Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies
    Nyberg, Joakim
    Bazzoli, Caroline
    Ogungbenro, Kay
    Aliev, Alexander
    Leonov, Sergei
    Duffull, Stephen
    Hooker, Andrew C.
    Mentre, France
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (01) : 6 - 17
  • [27] PHARMACOKINETICS/PHARMACODYNAMICS POPULATION MODELING OF TRANSAMINITIS IN CANCER PATIENTS TREATED WITH KAHALALIDE F
    Miguel-Lillo, B.
    Duart, M. J.
    Soto-Matos, A.
    Valenzuela, B.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 20 - 20
  • [28] POPULATION MODELING OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PONESIMOD, A SELECTIVE SIPI RECEPTOR AGONIST.
    Krause, A.
    Brossard, P.
    D'Ambrosio, D.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S36 - S37
  • [29] A new approach to modeling covariate effects and individualization in population pharmacokinetics-pharmacodynamics
    Lai, TL
    Shih, MC
    Wong, SP
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (01) : 49 - 74
  • [30] A New Approach to Modeling Covariate Effects and Individualization in Population Pharmacokinetics-Pharmacodynamics
    Tze Leung Lai
    Mei-Chiung Shih
    Samuel P. Wong
    Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33 : 49 - 74
12345